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Intermittent hypoxiaSleep apnea syndrome (SAS) is considered to be associated with heart failure (HF). It is known that autophagy is
induced in various heart diseases thereby promotes survival, but its excess may be maladaptive. Intermittent
hypoxia (IH) plays pivotal role in the pathogenesis of SAS. We aimed to clarify the relationships among IH,
autophagy, and HF. Rats underwent IH at a rate of 20 cycles/h (nadir of 4% O2 to peak of 21% O2 with 0% CO2)
or normal air breathing (control) for 8 h/d for 3 weeks. IH increased the cardiac LC3II/LC3I ratio. The IH induced
upregulation of LC3II was attenuated by the administration of an inhibitor of autophagosome formation
3-methyladenine (3-MA), but enhanced by an inhibitor of autophagosome–lysosome fusion chloroquine (CQ),
showing enhanced autophagic ﬂux in IH hearts. Electron microscopy conﬁrmed an increase in autophagosomes
and lysosomes in IH. With 3-MA or CQ, IH induced progressive deterioration of fractional shortening (FS) on
echocardiography over 3 weeks, although IH, 3-MA, or CQ alone had no effects. With CQ, IH for 4 weeks in-
creased serum troponin T levels, reﬂecting necrosis. Western blotting analyses showed dephosphorylation of
Akt and mammalian target of rapamycin (mTOR) at Akt (Ser2448, 2481) sites, suggesting the activation of
autophagy via Akt inactivation. Conclusions. IH-mediated autophagy maintains contractile function, whereas
when autophagy is inhibited, IH induces systolic dysfunction due to myocyte necrosis. General signiﬁcance.
This study highlighted the potential implications of autophagy in cardio-protection in early SAS patients without
comorbidity, reproduced in normal rats by 3 ~ 4 weeks of IH.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Sleep apnea syndrome (SAS) has been implicated in increased
cardiovascular risk related to pulmonary hypertension, systemic
hypertension, heart failure (HF), coronary artery disease, and cardiac
arrhythmias [1–4]. The prevalence of obstructive SAS (OSAS) in pa-
tients with heart failure ranges from 15% to 50%, and the mortality
rate of patients with severe OSAS is signiﬁcantly higher [1–4]. Addi-
tionally, cardiac function is impairedwith left ventricular hypertrophy
in obese patients with severe OSAS [5]. Hypertension, cardiac remod-
eling, and other complications of SAS have been studied using rodent
models of intermittent hypoxia (IH) induced by short cycles of hypox-
ia–normoxia [6]. However, few studies have addressed contractile
function related to IH [7–9], and only one study has thus far examined
the mechanisms underlying contractile dysfunction [9].+81 3 5841 3366.
da).
rights reserved.During autophagy, cytoplasmic proteins and organelles seques-
tered in double-membrane vesicles (autophagosome) are delivered
to lysosomes for degradation, acting as energy sources for survival
in response to nutrient deﬁciency or various stresses [10]. Autophagy
also promotes cell survival through degradation and recycling of
long-lived proteins, misfolded proteins, ubiquitinated proteins, and
injured organelles in models of various heart diseases [11–14].
Using pharmacological inhibition of autophagy, we have previously
demonstrated that autophagy suppresses the progression of HF in
myocardial infarction and starvation [15,16]. Similarly, accumulating
evidence has indicated beneﬁcial roles of autophagy [17], although
results from a few studies have also shown detrimental effects in ro-
dent models of hypertensive and other heart diseases [18,19]. Upon
incorporation in the autophagosome membrane through phosphati-
dylethanolamine conjugation, LC3I is transformed to LC3II with faster
electrophoretic mobility, and the LC3II (transformation) is a reliable
marker of autophagy [10]. In addition, 3-MA and CQ inhibit initiation
of autophagosome formation and autophagosome–lysosome fusion,
respectively [10,19].
Table 1
Biometric parameters of control (C), chloroquine (CQ)-treated, intermittent hypoxia
(IH), and CQ-treated IH rats at 3 weeks.
C
(n = 7)
CQ
(n = 7)
IH
(n = 8)
IH + CQ
(n = 5)
HW (g) 0.78 ± 0.033 0.73 ± 0.014 0.78 ± 0.026 0.70 ± 0.015
BW (g) 299 ± 10.1 283 ± 6.67 288 ± 6.69 253 ± 5.17⁎⁎†
HW/BW (‰) 2.60 ± 0.077 2.60 ± 0.031 2.74 ± 0.056 2.78 ± 0.052
RBC
(×10 μL−4)
774.6 ± 34.9 767.0 ± 30.9 816 ± 48.0 833.7 ± 38.7⁎†
Hb (g/dL) 14.7 ± 0.68 14.5 ± 0.65 15.6 ± 0.79† 15.6 ± 0.57†
Ht (%) 43.3 ± 1.84 42.9 ± 1.79 46.4 ± 2.79⁎⁎†† 46.0 ± 1.27⁎
HW, heart weight; BW, body weight; RBC, red blood cell count; Hb, hemoglobin; Ht,
hematocrit. ⁎P b 0.05 vs. C, ⁎⁎P b 0.01 vs. C, †P b 0.05 vs. CQ, ††P b 0.01 vs. CQ (Tukey–
Kramer test). Values are presented as mean ± SE (n, numbers of rats).
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plexes 1 and 2 (mTORC1 and mTORC2) [20,21]. Autophagy is constitu-
tively repressed by mTORC1, and diverse stimuli or stress induces
autophagy through mTORC1 inactivation either by the activation of
the adenosine monophosphate-activated protein kinase (AMPK) path-
way or by inhibition of the Akt pathway. AMPK phosphorylates tuber-
ous sclerosis 2 (TSC2), and inhibits RHEB (mTOR activator protein)
activation, resulting inmTORC1 inactivation [20,21]. AMPK also inhibits
mTOR activity either through direct phosphorylation of mTORC1 at
Threonine 2446 or phosphorylation of the mTORC1 binding partner
Raptor [22,23]. In contrast, Akt enhances the phosphorylation and inhi-
bition of TSC2, thereby relieving the TSC2-dependent inhibition of RHEB
toward mTOR [20,21]. Additionally, Akt induces the phosphorylation of
mTOR at Ser2448 [22] as well as at Ser2481, which are reliable markers
of mTOR-speciﬁc catalytic activity downstream of the PI3 kinase–Akt
pathway [24]. Collectively, AMPK inhibits and Akt activates mTOR,
thereby regulating autophagy.
Given that IH plays a pivotal role in SAS, we aimed to clarify
whether and how IH induces autophagy in the rat heart, and if it
does, whether the autophagy is implicated in contractile dysfunction
(HF) and cardiac injury related to IH.
2. Materials and methods
2.1. Animal model
All experiments were performed according to the Guide for the
Care and Use of Laboratory Animals published by the US National In-
stitutes of Health (NIH publication 85-23, revised 1996). The protocol
was approved by the Institutional Animal Care and Use Committee of
the University of Tokyo.
Male 7-week-old Sprague–Dawley rats underwent intermittent
hypoxia (IH) at a rate of 20 cycles/h (nadir 4% O2 to peak 21% O2
with 0% CO2), or room air breathing (control) in the same plastic
cage placed next to the cage equipped with the IH apparatus for
8 h/d during the “light on” period of 12 h. The IH rats were allowed
free access to food and water, while the amount of food for control
rats was restricted to adjust their average body weight comparable
to that of the IH rats every week. Four other groups of rats were intra-
peritoneally (i.p.) injected with either 3-methyladenine (3-MA,
15 mg/kg/d; Sigma-Aldrich, St. Louis, MO) or chloroquine (CQ,
20 mg/kg/d, Wako Pure Chemical Industries, Ltd., Osaka, Japan),
both dissolved in saline, and exposed to IH or air. After the ﬁnal echo-
cardiography evaluation at 3 weeks, the rats were anesthetized by an
i.p. injection of sodium pentobarbital and euthanized. The left ventri-
cle and trunk blood were harvested and stored at −80 °C until anal-
yses. Four other groups of rats (control, CQ, IH, and IH + CQ) were
observed for 4 weeks. The numbers of animals included in each
group are described in the tables and ﬁgure legends. A rat model of
myocardial ischemia (30 min)–reperfusion (6 h), produced by coro-
nary ligation, served as a positive control for cell death study.
2.2. Echocardiographic studies
Echocardiography was performed under inhalational anesthesia
with isoﬂurane (Mylan Inc., 2.5 L/min), using prosound α 10 (Aloka
Co., Ltd., Tokyo, Japan). A 2D parasternal short-axis view of the LV
was obtained at the level of the papillary muscles. When suitable im-
ages on the axis were obtained, 2D targeted M-mode tracings were
recorded. Two consecutive heartbeats of each frame were analyzed
to measure the heart rate (HR), LV anterior wall thickness in diastole
(LVAWd) and systole (LVAWs), LV posterior wall thickness in diastole
(LVPWd) and systole (LVPWs), end-diastolic LV internal dimensions
(LVDd), and endo-systolic LVD (LVDs). LV fractional shortening (FS)
was calculated as LVDd minus LVDs normalized for LVDd, as an
index for LV systolic performance. We conﬁrmed very small intra-and inter-observer variability along with high reproducibility in the
same animals as those used in our echocardiographic measurements.
2.3. Electron microscopy
Cardiac tissue was rapidly cut into 1-mm cubes, immersion-ﬁxed
in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) overnight
at 4 °C, and post-ﬁxed in 1% buffered osmium tetroxide. The speci-
mens were then dehydrated through a graded ethanol series and em-
bedded in epoxy resin. Ultrathin sections (90 nm), double-stained
with uranyl acetate and lead citrate, were examined using an electron
microscope (H-800; Hitachi, Tokyo, Japan).
2.4. Western blot analysis
The homogenate proteins from frozen hearts were resolved on
SDS-PAGE (15% gels for LC3B, caspase-3, and actin; 10% gels for AMPK,
Akt, and GAPDH; and 5% gels formTOR and N-cadherine) and subjected
to western blotting. The blots were probed with one of the primary an-
tibodies: LC3B (#2775), AMP kinase (#2532), AMP kinase phospho-
Thr172 (#2535), Akt (#9272), Akt phospho-Ser473 (#9271), mTOR
(#4517), mTOR phospho-Ser2448 (#2971), capase-3 (#9665) (all
from Cell Signaling, Danvers, MA), GAPDH (Abcam, Richmond, Canada),
actin (Sigma-Aldrich, St. Louis, MO), and N-cadherin (BD Transduction
Lab, Flanklin Lakes, NJ). For chemiluminescence detection and the sec-
ondary antibody, we used peroxidase-conjugated anti-mouse IgG or
anti-rabbit IgG (Promega, Madison, WI). The band densities were mea-
sured using ImageQuantTM LAS 4000 mini (GE Healthcare UK Ltd.,
Buckinghamshire, England).
2.5. Statistical analysis
Group data are expressed as mean ± SE. The data were analyzed
using Dunnett's test, the Tukey–Kramer test, or Student's t-test at a
conﬁdence level of 95%.
3. Results
3.1. Inﬂuence of IH and autophagy inhibitors on hematology, body
weight, and heart weight
As compared with the control rats, rats that underwent IH for
3 weeks showed increased hemoglobin concentrations, hematocrit
values, and red blood cell counts (Table 1), reﬂecting polycythemia
resulting from systemic hypoxia. Body weight (BW) did not differ be-
tween the groups until 2 weeks (data not shown). However, at
3 weeks, the BW was reduced in the IH + CQ group as compared
Table 2
Biometric parameters of control (C), 3-methyladenine (MA)-treated, intermittent hypoxia (IH), and MA-treated IH rats at 3 weeks.
C
(n = 4)
MA
(n = 5)
IH
(n = 6)
IH + MA
(n = 6)
HW (g) 0.69 ± 0.004 0.59 ± 0.015⁎⁎ 0.61 ± 0.013⁎⁎ 0.64 ± 0.013
BW (g) 268 ± 6.64 246 ± 4.78 235.7 ± 4.01⁎⁎ 246 ± 5.16⁎⁎§
HW/BW (‰) 2.59 ± 0.061 2.40 ± 0.045 2.58 ± 0.039 2.59 ± 0.033
RBC (×10 μL−4) 774.8 ± 26.4 756.4 ± 27.9 845.2 ± 11.0§ 855.3 ± 19.9§
Hb (g/dL) 14.9 ± 0.26 14.3 ± 0.5 16.2 ± 0.14⁎§§ 16.3 ± 0.26⁎§§
Ht (%) 44.0 ± 0.91 42.3 ± 1.08 45.0 ± 0.39§ 46.9 ± 0.42⁎§§
⁎P b 0.05 vs. C, ⁎⁎P b 0.01 vs. C, §P b 0.05 vs. MA, §§P b 0.01 vs. MA (Tukey–Kramer test). Values are presented as mean ± SE (n, numbers of rats).
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been rapidly reduced in weeks 2–3, possibly due to progressive sys-
tolic dysfunction. On the other hand, since the heart weight (HW)
was reduced along with the BW, the HW/BW ratio in the IH + CQ
group did not differ from those in the IH and control groups. CQ had
no discernible adverse effects on the hematology, HW, and BW. Like-
wise, 3-MA had neither any additional effect on the IH group nor any
toxic effect on the C group (Table 2).
3.2. IH induces autophagy
Following the incorporation of LC3I in the autophagosome mem-
brane through phosphatidylethanolamine conjugation, this molecule
transforms to LC3II with faster electrophoretic mobility. Accordingly,
the LC3II level and LC3II/LC3I ratio has been demonstrated to be reli-
able markers for autophagy [10,19]. We found an increase in the LC3II
abundance and the LC3II/LC3I ratio in IH hearts (Fig. 1). 3-MA and CQ
are known to inhibit the initiation of autophagosome formation and
autophagosome–lysosome fusion, respectively [10,19]. We found
that 3-MA suppressed, and CQ enhanced the IH-induced upregulation
of LC3II, conﬁrming enhanced autophagic ﬂux in IH hearts.LC
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Fig. 1. IH increased LC3II abundance and the LC3II/I ratio in LV, which were further el-
evated by the administration of the autophagy inhibitor CQ, or attenuated by 3-MA.
Panels A–D show representative western blots and the quantiﬁcation, respectively.
Values are presented as a ratio to the mean value of the control (mean ± SE, each
group n = 5–11). ⁎P b 0.05 vs. C, ⁎⁎P b 0.01 vs. C, ††P b 0.01 vs. CQ, §P b 0.05 vs. MA,
§§P b 0.01 vs. MA, ‡‡P b 0.01 vs. IH (Tukey–Kramer test).Electron microscopy conﬁrmed an increase in the number of
autophagosomes in the ventricle after IH for 3 weeks (Fig. 2). Some
autophagosomes contained mitochondria that were mostly swollen
in appearance with a low electron density. We also found an increaseB 
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*
Fig. 2. Electron microscopic images of rat hearts after 3 weeks of IH. Compared with
the control (A), IH induced swelling of the mitochondria with low electron density,
some of which were engulfed by the autophagosomes (B: low, C: high magniﬁcation),
and increased lysosomes with high electron density (B). See “arrows” for
autophagosomes, “arrowheads” for lysosomes, “asterisks” for swollen mitochondria
in autophagosomes, and “N” for nuclei. Scale bar = 1 µm.
Table 3
Echocardiographic parameters of control (C), chloroquine (CQ)-treated, intermittent hypoxia (IH), and CQ-treated IH rats at 3 weeks.
C
(n = 10)
CQ
(n = 10)
IH
(n = 11)
IH + CQ
(n = 9)
FS (%) 54.94 ± 1.28 55.85 ± 1.83 54.77 ± 2.82 44.23 ± 2.03⁎⁎ †† ‡‡
LVAWd (mm) 1.51 ± 0.068 1.51 ± 0.040 1.55 ± 0.073 1.39 ± 0.048
LVAWs (mm) 2.84 ± 0.10 2.76 ± 0.073 2.86 ± 0.15 2.29 ± 0.068⁎⁎ † ‡‡
LVDd/BW (mm/100 g) 2.32 ± 0.074 2.38 ± 0.056 2.30 ± 0.060 2.48 ± 0.069
LVDs/BW (mm/100 g) 1.05 ± 0.061 1.05 ± 0.061 1.05 ± 0.082 1.38 ± 0.067⁎ † ‡
LVPWd (mm) 1.92 ± 0.35 1.78 ± 0.37 1.90 ± 0.27 1.80 ± 0.45
LVPWs (mm) 3.08 ± 0.32 3.05 ± 0.26 3.06 ± 0.51 2.61 ± 0.40
HR (bpm) 354.4 ± 39.3 350.0 ± 13.8 392.0 ± 34.8 362.8 ± 48.6
FS, fractional shortening; LVAWd, left ventricular (LV) anterior wall (AW) thickness in diastole; LVAWs, LVAW thickness in systole; LVDd, LV end-diastole dimension (LVDd); LVDd,
LV end-systolic diameter; LVPWd, LV posterior wall (PW) thickness in diastole; LVPWs, LVPW thickness in systole; HR, heart rate. Values are presented as mean ± SE.
Table 4
Echocardiographic parameters of control (C), 3-methyladenine (MA)-treated, intermittent hypoxia (IH), and MA-treated IH rats at 3 weeks.
C
(n = 4)
MA
(n = 5)
IH
(n = 6)
IH + MA
(n = 6)
FS (%) 59.32 ± 1.77 55.65 ± 1.32 53.92 ± 1.37 44.48 ± 1.33⁎⁎ §§ ‡‡
LVAWd (mm) 1.46 ± 0.031 1.43 ± 0.029 1.43 ± 0.057 1.44 ± 0.071
LVAWs (mm) 2.82 ± 0.09 2.69 ± 0.064 2.73 ± 0.10 2.51 ± 0.13⁎⁎ § ‡‡
LVDd/BW (mm/100 g) 2.35 ± 0.091 2.49 ± 0.216 2.61 ± 0.091 2.63 ± 0.141
LVDs/BW (mm/100 g) 0.96 ± 0.053 1.11 ± 0.055 1.20 ± 0.053 1.47 ± 0.060⁎⁎ §§‡‡
LVPWd (mm) 1.93 ± 0.13 1.74 ± 0.12 2.03 ± 0.11 1.78 ± 0.10
LVPWs (mm) 2.74 ± 0.14 2.79 ± 0.03 2.96 ± 0.11 2.44 ± 0.09‡‡
HR (bpm) 366.8 ± 22.1 372.5 ± 13.0 357.2 ± 20.1 345.1 ± 12.1
⁎P b 0.05 vs. C, ⁎⁎P b 0.01 vs. C, §P b 0.05 vs. MA, §§P b 0.01 vs. MA, ‡P b 0.05 vs. H, ‡‡P b 0.01 vs. IH (Tukey–Kramer test). Values are presented as mean ± SE (n, numbers of rats).
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after 3 weeks of IH. Values are presented asmean ± SE. ⁎⁎P b 0.01 vs. C, ††P b 0.01 vs. CQ.
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density, consistent with lyososomes [15,16] after IH, as compared
with the controls (Fig. 2).
3.3. With autophagy inhibition, IH induces contractile dysfunction
Echocardiographic data at the end-point (3 weeks) (Tables 3 and 4)
and temporal changes in FS (Fig. 3) showed no differences in between
the control (IA), CQ, 3-MA, and IH groups at 3 weeks (Tables 3 and 4).
However, when CQ or 3-MA was administered, the FS of the IH rats
gradually decreased until 3 weeks (Fig. 3), and the decline became
signiﬁcant at 3 weeks as compared with the control, IH, 3-MA, and
CQ groups (Tables 3 and 4). FS marginally deteriorated at 4 weeks of
IH + CQ (41.02 ± 4.60), as compared with that at 3 weeks (44.23 ±
2.03). These data show that contractile function was maintained in
the IH heart at least for 4 weeks, whereas systolic performance deterio-
rated with time in the presence of the autophagy inhibitor.
We conﬁrmed the speciﬁcity and safety of the doses of 3-MA and CQ
in our preliminary experiments, based on results from previous studies
[16,19]. The intraperitoneal injection of 3-MA at 15 mg/kg/d or CQ at
20 mg/kg/d for 3 d did not affect either the basal physiological and
echocardiographic parameters or the LC3II levels (data not shown).
However, the same dose of 3-MA or CQ enhanced starvation-induced
systolic dysfunction and LC3II upregulation over 3 d.
3.4. Myocardial injury and cell death
The systolic dysfunction demonstrated by echocardiography could
have been caused by the abnormal mitochondria, some of which were
sequestered in autophagosomes in the IH hearts, as demonstrated by
electron microscopy (Fig. 2). However, we could ﬁnd no differences in
the mitochondria and autophagosomes between the IH and IH + CQ
groups (data not shown). Additionally, although cardiac remodeling is
known to cause systolic dysfunction, the histological examination of
1163H. Maeda et al. / Biochimica et Biophysica Acta 1832 (2013) 1159–1166the hearts of rats from the IH or IH + CQ groups demonstrated neither
ﬁbrosis nor ventricular wall thickening (Fig. 4).
Systolic dysfunction can also be induced by cell death. Serum tropo-
nin T was increased in the rats that underwent IH + CQ for 4 weeks,
indicating sarcolemmal disruption related to myocardial necrosis
(Fig. 5A). In contrast, IH, 3-MA, or CQ alonehadno such effect.Moreover,
serum aspartate aminotransferase levels (AST) were increased signiﬁ-
cantly, although to a much lesser extent than the troponin T levels
(Fig. 5B), in the IH + CQ group, reﬂecting more severe injury in the
heart as compared to that in the other organs.
There has been abundant evidence for cross-talk between autoph-
agy and apoptosis [11]. However, IH exerted a negligible effect onFig. 4. Horizontal section of hearts (A–D) and LV histology (E–H) in control (A, E), CQ (B, F),
ﬁbrosis was apparent in any of the sections. Scale bar = 20 µm.caspase-3 fragmentation, an indicator for apoptosis, on western blot-
ting (Fig. 5C).
3.5. Signaling pathway for the induction of autophagy
We examined autophagy-related signaling molecules by western
blot analyses. IH for 3 weeks reduced the phosphorylation of Akt-
serine (Ser) 473 relative to total Akt, but not the phosphorylation
of AMPK-threonine (Thr) 172 (Fig. 6). Treatment with 3-MA or CQ
did not affect these results (data not shown). IH also decreased
the phosphorylation of mTOR at Ser 2448 (Akt site) and at Ser 2481
(autophosphorylation site downstream of PI3 kinase/Akt pathway)IH (C, G), and IH + CQ (D, H) rats (Elastica–Masson staining). Neither hypertrophy nor
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Fig. 5. Effect of CQ with IH for 4 weeks. The serum levels of troponin T (A) and aspar-
tate amino transferase (AST) (B) were increased. Values are presented as mean ± SE.
Numbers of rats indicated for (C), (IH), (CQ), and (IH + CQ). ⁎⁎P b 0.01 vs. C,
††P b 0.01 vs. CQ. ‡‡P b 0.01 vs. IH (Tukey–Kramer test). PC indicates positive control.
1164 H. Maeda et al. / Biochimica et Biophysica Acta 1832 (2013) 1159–1166(Fig. 6) [22,24]. Consistent with no changes in AMPK phosphoryla-
tion, IH had no effect on the phosphorylation of mTOR at Thr 2446
(AMPK site) (Fig. 6) [22,23]. These data support that mTOR was
inactivated through the inhibition of Akt but not the activation of
AMPK.
4. Discussion
This is the ﬁrst report describing the autophagy induced by IH in an
animal model of SAS. During 3 ~ 4 weeks of IH, the LV systolic function
was maintained by autophagy. However, systolic dysfunction and ne-
crosis emerged when autophagy was inhibited by 3-MA or CQ.
4.1. IH enhances autophagy
IH increased the LC3II level and the LC3II/LC3I ratio in western blot-
ting analysis (Fig. 1) as well as the numbers of autophagosomes and ly-
sosomes in electron microscopy (Fig. 2). Further, the LC3II abundance
was reduced by 3-MA and increased by CQ (Fig. 1). Given that 3-MA
inhibits autophagosome formation and CQ inhibits autophagosome–
lysosome fusion [10,19], these data indicate enhanced autophagy
ﬂux with IH.
The cardiotoxicity of 3-MA and CQ was negligible since the doses of
3-MA and CQ used herein did not affect the baseline cardiac functions,
dimensions, heart rate, or hematological parameters (Tables 1 and 2;Fig. 3). In support of our data, it has been previously reported that CQ
is safer, cheaper, and more suitable for in vivo use than baﬁlomycin A
[19]. Meanwhile, the effect of 3-MA has been questioned due to its con-
tradictory effects on autophagy in different phases [25]. Additionally, a
much higher dose of 3-MA (100 mg/kg vs. 15 mg/kg in this study)
was used in rats to examine the role of autophagy in adriamycin-
cardiotoxicity [26]. However, our results concerning the effects of
3-MA and CQ at the given doses on the increase in LC3II levels in IH
(Tables 1 and 2; Figs. 1 and 3)were consistentwith the expected effects
of these inhibitors [10].
4.2. Inhibition of autophagy induces systolic dysfunction in IH heart
During 3 ~ 4 weeks of IH, the cardiac function did not alter. How-
ever, with the administration of the autophagy inhibitors 3-MA and
CQ, IH progressively reduced the FS and increased LVDs (Tables 3
and 4; Fig. 3), consistent with systolic dysfunction. These ﬁndings
demonstrate that the ﬂux of autophagy is enhanced by IH, and serves
in maintaining systolic function. However, if autophagy activity were
low due to medication or disease conditions that impair the processes
or signaling in autophagy, IH would induce systolic dysfunction and
eventually HF.
From the functional viewpoint, the systolic dysfunction in IH +
3-MA or IH + CQ can result from impaired ventricular ﬁlling and
myocardial contractility, which is generally associated with LV re-
modeling and myocardial injury, according to a recent review on ro-
dent echocardiography [27]. LV remodeling is not likely to cause
systolic dysfunction since neither cardiac hypertrophy nor ﬁbrosis
was apparent in the IH + CQ group (Fig. 4, Tables 1 and 2). A reduc-
tion in LV end-diastolic volume (LVEDV) and cardiac output is known
to reduce LV ﬁlling [27]. However, these ﬁndings were not conﬁrmed
in the IH + CQ and IH + 3-MA groups (data not shown).
We observed that IH + CQ for 4 weeks induced myocardial necro-
sis, as demonstrated by troponin T release (Fig. 5). In cardiomyocytes,
we have previously reported that glucose deprivation induces necrosis
but not apoptosis following the inhibition of autophagy by 3-MA or
leupeptin [28]. In cardiomyopathic hamsters, we have also shown
that autophagic cardiomyocytes demonstrate dye permeation and co-
localization with lysosomal cathepsin B, but not TUNEL-positivity, indi-
cating a close relationship between autophagy and necrosis [29]. We
found no evidence for apoptosis, such as caspase-3 fragmentation
(Fig. 5) or TUNEL-positivity, in the rat hearts after IH + CQ (data
not shown). Moreover, Su et al. reported that the accumulation of
autophagosomes due to autophagy inhibition by the genetic deletion
of the COP9 signalosome, a regulator for ubiquitin-proteasome, or by
CQ administration in mice induces myocardial necrosis [30]. We did
not observe troponin T release or contractile dysfunction following
the administration of CQ alone for 4 weeks (Fig. 5). However, the
anti-necrotic effect of autophagy is common to their and our studies de-
spite of difference in animal species. It is noteworthy that ATP depletion
favors necrosis rather than apoptosis [11], whereas autophagy pro-
motes an energy supply for adaptation and survival in response to stress
[10].
Together with these ﬁndings, we estimated that when autophagy
is inhibited, IH induced LV systolic dysfunction and necrosis, possibly
through the accumulation of autophagosomes containing harmful
substances. Indeed, in the rats that underwent IH, we found an abun-
dant number of autophagosomes with abnormal mitochondria that
could enhance the generation of reactive oxygen species and lead to
futile ATP consumption (Fig. 2) [31]. However, further analyses are
required, as we found no apparent differences in the mitochondria
and autophagosomes between the IH and IH + CQ groups.
Consistent with our results, 2 studies have previously demonstrated
normal echocardiographic ﬁndings in mice following short IH. In one of
these studies, no systolic dysfunctionwas detected after IH for 4 weeks,
although a paradoxical increase in the stroke volume, cardiac output,
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Fig. 6. Effect of IH for 3 weeks on autophagy-related kinases. Representative western blots (A) and the quantiﬁcation of the phospho-protein, total proteins, their ratio to actin, and
the ratio of the phospho-protein to total protein (ratio to the mean value of the LV control) are shown on Akt-Ser473 (B), AMPK-Thr172 (C), mTOR-Ser2448, mTOR-Ser2481 and
mTOR-Thr2446 (D). Values are presented as a ratio to the mean value of the control mean ± SE (each group n = 5–11). ⁎P b 0.05 vs. C, ⁎⁎P b 0.01 vs. C (Tukey–Kramer test).
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the other study, 10 d of IH enhanced LV systolic function and RV
pressure-loading [8]. In contrast, IH for a longer duration, i.e., 8 weeks,
induced LV systolic dysfunction, LV dilation, LV hypertrophy, apoptosis,
and fetal genes [9]. Thus, short-term IH,which simulates the early phase
of SAS, would induce autophagy, thereby promoting cardiac adapta-
tions that maintain or even enhance systolic function in response to
hypoxic and hemodynamic stress.
In pressure-overloaded hearts, autophagy is either adaptive or
maladaptive [17]. Atg5-deﬁciency-mediated inhibition of “adaptive
autophagy” enhances LV hypertrophy and cardiac dysfunction, even-
tually leading to HF in response to trans-aortic constriction (TAC) in
mice [13]. In contrast, Beclin 1 haploinsufﬁciency improves cardiac
performance in mice post-TAC but does not affect LV hypertrophy,
reﬂecting “maladaptive autophagy” [18]. The discrepant effects of au-
tophagy in these studies have been interpreted such that maladaptive
autophagy is considered to occur when it is deﬁcient or excessive in
severity or duration [17]. In a rat model of chronic myocardial infarc-
tion, we have previously reported that cardiac hypertrophy and
contractile dysfunction are aggravated by the administration of anautophagy inhibitor (baﬁlomycin A1) and improved by the adminis-
tration of an autophagy activator (rapamycin) [15], reﬂecting “adap-
tive autophagy.” Similarly, the autophagy in IH, as noted in the
present study, would be adaptive in nature.
4.3. Clinical implications
Zhu et al. argued that moderate declines in FS over 3 weeks of TAC
in mice are clinically signiﬁcant [18], because an epidemiological
study has demonstrated that moderate declines in systolic functions
can predict the long-term prognosis of HF [32]. We consider that
the 12% decline (from 56% to 44%) in FS with IH + CQ over 3 weeks
is signiﬁcant (Fig. 3), given the short IH duration in normal rats.
Epidemiologically, whether SAS is a risk factor for HF has been con-
troversial [1–4]. In the 2058 Sleep Heart Health Study participants, a
higher Apnea–Hypoxemia Index (AHI) was associated with larger LV
diastolic dimensions and a lower ejection fraction; however, a history
of congestive HF accounted for only 6.4% of the SAS patients even
among the highest (>30) AHI group [2]. SAS morbidity in HF patients
appears to be somewhat higher [1,3]. In any case, the comorbidity of
1166 H. Maeda et al. / Biochimica et Biophysica Acta 1832 (2013) 1159–1166HF and SASwould bemuch higherwere it not for the enhanced autoph-
agy in the early phase of SAS, as suggested by the present study.We be-
lieve that the enhancement of autophagy is a potential new strategy for
the treatment or prevention of HF in early-phase SAS patients.
In the SAS population, many patients with HF are likely to suffer
from hypertension, diabetes, obesity, or coronary heart diseases [1–4].
However, we conducted this study using normal rats with 3–4-week
study periods, stimulating the early phase of SAS without any
confounding factors. Indeed, Zhu et al. pointed out the importance of
autophagy research in model animals for chronic diseases [18]. Accord-
ingly, we conducted a preliminary study and conﬁrmed the deleterious
effects of IH on cardiac function in diseased rats (data not shown).
4.4. Signaling pathway for autophagy in IH
mTOR, the universal repressor of autophagy, is inhibited through in-
direct phosphorylation byAMPkinase at Thr2446, and activated through
indirect phosphorylation by Akt at Ser2448/2481 [20–24]. We observed
that IH induced the dephosphorylation of mTOR at the Akt sites
(Ser2448/2481), consistent with the dephosphorylation of Akt-Ser473
(Fig. 6). However, IH affected neither mTOR phosphorylation at the
AMPK site (Thr2446) nor AMPK phosphorylation (Fig. 6). Thus, the re-
pression of Akt-mTOR pathway is likely to induce the autophagy in IH.
5. Conclusion
IH induces autophagy, which maintains contractile function and
prevents necrosis in the heart of normal rats. Our results highlighted
the cardio-protective roles of autophagy in the early phase of SAS.
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